Today, the Medicines and Healthcare products Regulatory Agency (MHRA) launches a landmark public consultation on a proposed new regulatory framework that will spearhead the development of rare disease treatment in the UK. This framework – which sets out a new model for how rare disease therapies for individuals could be tested, licensed and monitored – […]